HTA and Payers Stakeholder Advisory Group formed

The needs and requirements of HTA agencies and Payers regarding patient preferences differ from those of the regulators. Both focus on risk-benefit assessment, but HTA bodies and reimbursement agencies are also interested in the relative effectiveness of a product.  To make sure that their needs and requirements are taken into account, PREFER has formed a HTA and Payers Stakeholder Advisory Group.

PREFER aims to establish recommendations to support development of guidance for industry, Regulatory Authorities and HTA bodies on how and when patient perspectives on benefit and risk should be considered in the product life-cycle. And when this should inform the decision-making process by regulatory authorities and HTA bodies. To meet this goal, PREFER is engaging stakeholders who represent a wide spectrum of entities and countries to make sure their views are duly considered.

The HTA and Payers advisory group is co-ordinated by the Belgian Health Care Knowledge Centre (KCE), the Belgian HTA-agency. Other members of this stakeholder advisory group are CADTH, (the Canadian Health Technology Assessment Agency), NIHDI (Belgian National Institute for Health and Disability Insurance) and G-BA (Gemeinsamer Bundesausschuss, the German reimbursement agency). EUnetHTA, the European network for HTA, is also represented.

This group will ensure that the needs and requirements of the HTA bodies and Payers are taken into account in the development of the PREFER project and its recommendations.

Read about HTA in PREFER (Link removed)

By Gudrun Briat & Irina Cleemput, Belgian Health Care Knowledge Centre (KCE)

Note: Since October 2016, the Swedish Agency for Health Technology Assessment and Assessment of Social  Services (SBU) is also a part of the HTA and payer stakeholder advisory group.

CONTACT US

X: @IMI_PREFER

LinkedIn

YouTube

  •  
  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
  •  

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).